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Purpose: The endovascular approach to external iliac artery (EIA) disease extending into the common femoral artery
(CFA) has been avoided because of problems with stent placement across the inguinal ligament. Surgical treatment for
this disease distribution includes extensive endarterectomy or bypass procedures or both. We report our initial experience
with a combined open and endovascular approach to these patients.
Methods: We performed a retrospective analysis of all patients who underwent intraoperative EIA stenting after CFA
endarterectomy/patch angioplasty between 1997 and 2000. Stents were positioned to end at the proximal endarterec-
tomy endpoint, without crossing the inguinal ligament. Technical success, hemodynamic success, and clinical success were
determined according to Society of Vascular Surgery/International Society of Cardiovascular Surgery criteria. Life-table
analysis was performed for patency.
Results: Thirty-four patients (mean age, 68 years; 23 male, 11 female) had combined endovascular and open treatment of
iliofemoral occlusive disease. Indications were claudication in 41% and critical limb ischemia in 59%. Femoral reconstruc-
tion included endarterectomy with patch angioplasty in all patients. EIA stent deployment incorporated the stenotic iliac
segment and the proximal endpoint of the endarterectomy in all patients. Four patients (12%) also needed common iliac
angioplasty at the same time for proximal iliac disease, and 14 patients (41%) also needed distal revascularization for
associated femoropopliteal or tibial disease. Technical success and hemodynamic success were achieved in 100% of
patients. Clinical success was achieved in 97% of patients. The mean postoperative increase in ankle-brachial index in
patients with inflow procedures only was 0.36 (range, 0.1 to 0.85). The overall complication rate was 15%. With a mean
follow-up period of 13 months (range, 0.5 to 28 months), 1-year primary patency and primary-assisted patency rates were
84% and 97%, respectively. No perioperative mortality was seen.
Conclusion: EIA stenting as an adjunct to CFA endarterectomy/patch angioplasty allows for more localized surgery than
conventional bypass. This approach also allows a better interface between the stent and endarterectomy than staged
preoperative stenting. Technical success and early patency rates are excellent. (J Vasc Surg 2002;35:1107-13.)
The use of endarterectomy for occlusive disease of the
common femoral artery (CFA) has been standard practice
for more than 50 years. Patch arterioplasty with either
autogenous vein or more recently prosthetic patch material
is generally used and is usually performed to provide inflow
in concert with femoral-distal bypass or femoral-femoral
bypass. This approach provides satisfactory results in cases
of focal disease limited to the CFA and proximal superficial
femoral artery and profunda femoris artery. Cases in which
the diseased segment extends proximally into the external
iliac artery (EIA) present a more complex problem. The
best approach to complex iliofemoral disease is controver-
sial.1,2 Conventional approaches include extension of the
exposure proximally with division of the inguinal ligament
and extensive endarterectomy, separate transperitioneal or
retroperitoneal exposure, and more extensive aortofemoral
or iliofemoral bypass, femorofemoral bypass, or contralat-
eral iliofemoral bypass.3-8 These options carry with them
increased cardiopulmonary stress as the result of a more
extensive procedure and increased risk of complication,
such as femoral hernia or lymphedema.
Since the American Heart Association multidisciplinary
advisory committee report in 1994 suggesting bypass pro-
cedures to be superior to angioplasty/stenting for aor-
toiliac disease, we and several other groups have published
results for the use of interventional approaches for multi-
segment iliac occlusive disease.9-18 These groups have re-
ported patency rates of 55% to 77% for iliac angioplasty and
stenting, with assisted patency rates of nearly 90%, with
close follow-up and reintervention. The success of inter-
vention is dependent on the indication, gender, runoff,
lesion severity, and lesion location. The presence of EIA
stenosis is a predictor of poor outcome, and its severity can
be used to stratify patients with multisegment disease and
predict the durability of endovascular treatment.9 Endovas-
cular treatment has become standard for patients with focal
common iliac disease, with long-term patency rates of 70%
and clinical success rates in excess of 90%. Focal EIA disease
is less well studied, but reports suggest excellent results,
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with clinical improvement in this group as high as 98%.14
Extension of stenting across the inguinal ligament to incor-
porate CFA disease results in significantly poorer outcomes
because of damage of stents across a moving joint and an
increased development of intimal hyperplasia at these loca-
tions.19,20
Combined open and endovascular approaches to com-
plex vascular disease that does not conform to one treat-
ment approach are becoming more common as more vas-
cular surgeons have endovascular skills and results of
procedures performed in the operating room are favor-
able.21,22 The purpose of this study was to examine the
efficacy of a combined open and endovascular approach to
patients with long segment iliofemoral occlusive disease
with CFA endarterectomy and patch angioplasty with EIA
stenting.
METHODS
Between April 1997 and November 2000, 34 symp-
tomatic patients underwent CFA endarterectomy with
patch angioplasty and EIA angioplasty with primary stent-
ing in a single combined open and endovascular procedure
for treatment of extensive iliofemoral occlusive disease.
Retrospective review of the patient charts, duplex ultra-
sound scan findings, angiogram results, operative findings,
and procedural details was performed.
All patients underwent preoperative evaluation for pe-
ripheral vascular symptoms with duplex ultrasound scan
examination. This included evaluation for iliac arterial dis-
ease and ipsilateral runoff at least to the popliteal artery.
Patients with evidence for significant CFA occlusive disease
with proximal extension into the EIA were considered for
combined CFA endarterectomy and patch angioplasty with
EIA stenting. Preoperative or intraoperative arteriography
was performed to confirm these findings and further direct
treatment. The presence of significant CFA/EIA disease
was defined by an absent femoral pulse, a more than 2.5
peak systolic velocity step-up across the diseased CFA seg-
ment with duplex scan with more than 50% luminal nar-
rowing with B-mode imaging, a more than 50% diameter
reduction with angiographic imaging, or a more than 10
mm Hg systolic pressure gradient across the distal EIA at
the time of intraoperative angiography. Patients with con-
comitant severe superior femoral artery or distal disease
underwent simultaneous CFA endarterectomy/patch, EIA
stent, and distal bypass.
Operative procedure for CFA endarterectomy followed
the standard accepted technique. CFA was identified at the
inguinal ligament, the ligament was left intact, and expo-
sure was carried down to the femoral bifurcation. Puncture
of the CFA was performed to establish guidewire access
across the iliac lesion into the abdominal aorta with fluoro-
scopic guidance. Longitudinal arteriotomy was created,
and standard subintimal endarterectomy was performed,
with the distal endarterectomy ending as a fine tapering of
the CFA lesion into the superior femoral artery or profun-
dus femoris artery and the proximal endpoint cut flush just
proximal to the inguinal ligament with no attempt to
endarterectomize the more proximal EIA. Patch angio-
plasty then was performed with a standard elliptical Dacron
patch and running sutured anastomosis. Before completion
of the patch angioplasty, the patch was punctured in the
center with an 18-gauge needle, and the guidewire was
brought out through the center of the patch. After the
patch angioplasty was completed and flow was restored, a
7F short sheath was placed over the wire and through the
center of the patch. If guidewire access could not be ob-
tained initially with puncture, it was then attempted after
arteriotomy but before endarterectomy, and finally, if nec-
essary, after endarterectomy with direct vision. In cases in
which the guidewire could not be passed retrograde
through the arteriotomy, a percutaneous approach from
the contralateral femoral artery was used and the EIA
segment crossed antegrade by traversing the aortic bifurca-
tion. The guidewire then was snared and brought out
through the sheath placed through the patch. Intraopera-
tive arteriography then was performed with pressure mea-
surement across the EIA stenosis. Arterial diameter mea-
surements and measurements of the lesion were made after
standardizing the measurement software with either a
marker catheter or measurement of the sheath diameter.
Primary stenting with an appropriately sized self-expand-
ing, or less commonly balloon-expandable, stent (Wallstent
or Symphony nitinol stent, Boston Scientific, Boston,
Mass; Palmaz stent or Smart stent, Cordis, Miami Lakes,
Fla) was performed. Self-expanding stents were oversized
by 2 mm compared with either the normal appearing
proximal EIA or the contralateral EIA. Predialation was not
performed to minimize embolization risk. The distal end-
point of the stent was just distal to the proximal endarter-
ectomy ledge but above the inguinal ligament and encom-
passed the proximal tip of the Dacron patch. Poststent
balloon dilation was used at the surgeon’s discretion for
residual luminal narrowing after stent placement or if a
pressure gradient of more than 10 mm Hg existed after
stent placement.
Technical success was defined as complete resolution of
the stenosis angiographically and an unenhanced systolic
pressure gradient less than 10 mm Hg across the treated
distal EIA segment. Hemodynamic success was defined as an
increase in the ipsilateral ankle-brachial index (ABI) of at
least 0.1, according to the Society for Vascular Surgery/
American Association for Vascular Surgery reporting stan-
dards.23-25 Clinical success was defined with the American
Heart Association (AHA) classification (Table I).26
In this study, patency refers to the status of the EIA
stent segment and the CFA endarterectomy. It does not
refer to patency of femoral-distal bypass grafts in patients
who underwent additional revascularization. Postoperative
assessment of EIA stent patency began with evaluation for
recurrent symptoms, physical examination of an ipsilateral
femoral pulse, and segmental Doppler pressure recordings
with ABI. Patients who remained asymptomatic, had a
normal femoral pulse, and had a stable ABI were considered
to have a patent EIA/CFA. Patients with recurrent symp-
toms, a diminished femoral pulse, or a reduction in the ABI
JOURNAL OF VASCULAR SURGERY
June 20021108 Nelson et al
of more than 0.15 underwent duplex ultrasound scan ex-
amination to evaluate for patency or restenosis of the
EIA/CFA. A localized peak systolic velocity increase of
more than 2.5 was considered evidence for recurrent
stenosis. The decision for repeat endovascular intervention
for EIA stenosis was at the discretion of the vascular sur-
geon. Primary patency was defined as patency of the EIA/
CFA without evidence for restenosis or requirement for
reintervention, and primary-assisted patency was defined as
a patent artery that needed at least one repeat endovascular
intervention to treat a recurrent stenosis. Failure was de-
fined as the development of recurrent stenosis or occlusion
not amenable to endovascular reintervention.
Statistical analysis was performed with a computer-
based statistical software package (StatView, Abacus Con-
cepts, Inc, Berkeley, Calif). Patency rates were calculated
with the Kaplan-Meier life-table analysis method. Univari-
ate comparison of life-table curves was performed with
Mantel-Cox log-rank analysis. Logistic regression and Cox
proportional hazards model were used to evaluate factors
associated with procedural failure. Statistical significance
was assumed for a P value less than .05.
RESULTS
Complete data were obtained for all 34 patients who
underwent combined CFA endarterectomy and EIA stent-
ing during the study period. The demographics of the study
group are shown in Table II. The group was two-thirds
male, with a mean age of 68 years and a high incidence rate
of coronary artery disease, smoking, and hypertension.
Relatively few patients had diabetes, and no patient was
hemodialysis dependent. In 14 patients (41%), the indica-
tion for operation was claudication, and the remaining 20
patients (59%) had critical limb ischemia (10 rest pain, 10
tissue loss).
In all patients, CFA endarterectomy was necessary be-
cause of severe bulky disease or occlusion, and EIA stenting
was performed for the proximal extension of the plaque in
lieu of extending the endarterectomy. The mean length of
the EIA/CFA lesions was 5.0  0.6 cm. The breakdown
according to the AHA classification was grade 1 (3 cm),
18%; grade 2 (3 to 5 cm), 32%; grade 3 (5 to 10 cm), 36%;
and grade 4 (10 cm or occlusion), 14%. Fourteen patients
(41%) needed simultaneous femoral distal revascularization
for associated femoral-popliteal or tibial disease (10 femo-
ral-popliteal, four femoral-tibial). Four patients (12%)
needed simultaneous common iliac artery (CIA) angio-
plasty for separate isolated but hemodynamically significant
stenoses. Nine patients (27%) with critical limb ischemia
and the remaining seven patients with claudication under-
went CFA endarterectomy and EIA stenting alone. Three
of these patients had CFA occlusion. Technical success and
hemodynamic success were achieved in 100% of cases. The
mean improvement in systolic pressure gradient was 43 mm
Hg (45  5 mm Hg preprocedure to 2  0.7 mm Hg
postprocedure). The mean number of stents was 1.5 0.1
per patient and included Symphony (76%), Wallstent
(12%), Palmaz (8%), and Smart (4%). Symphony stents
were used preferentially for the standard retrograde ap-
proach. The remaining stents were used to treat the prox-
imal extent of the EIA lesion or were used in cases in which
a contralateral approach was used (n 7; 21%). The overall
complication rate was 15%, with two minor wound infec-
tions, one perioperative myocardial infarction, one mis-
placed stent deployed into the CIA, and one proximal
external iliac dissection treated via a brachial approach with
an additional stent at the time of the primary procedure. No
perioperative deaths were seen. One patient died during the
follow-up period from complications related to cancer.
Clinical improvement was achieved in all but one pa-
tient (97%). According to the AHA classification (Table
I),26 42% had grade 3 improvement, 35% grade 2, and 20%
grade 1, and a single patient (3%) had no improvement
(grade 0). No patient’s condition was made worse. For the
entire group, an overall mean increase in ABI of 0.41 was
found. The mean preoperative ABI was 0.38  0.04
(range, 0 to 0.8), and the mean postoperative ABI was
0.79  0.05 (range, 0.28 to 1.1). With exclusion of the
patients with simultaneous distal revascularization, the in-
crease in ABI from an inflow procedure alone was 0.36
(0.38  0.07 preprocedure to 0.74  0.07 postproce-
dure). One patient needed below-knee amputation later in
the follow-up period, despite a patent EIA stent, because of
Table I. American Heart Association guidelines for
clinical improvement
Grade Clinical description
3 Markedly improved; ABI 0.9
2 Moderately improved; ABI increase 0.1 but not normal,
and increase by one category
1 Minimally improved; ABI increase 0.1 but not normal,
or increase by one category
0 No change
–1 Mildly worse; no category decrease but ABI increase 0.1
–2 One category worse or unexpected minor amputation
–3 More than one category worse or unexpected major
amputation
Table II. Patient demographics
Characteristic Study group
Number 34
Gender 23 male; 11 female
Age (years) 68  2 (43-84)
Coronary disease 70%
Diabetes 26%
Hypertension 74%
Smoking 88%
Hyperlipidemia 37%
Renal failure —
Stroke —
COPD 37%
Claudication 41%
Rest pain 29.5%
Tissue loss 29.5%
COPD, Chronic obstructive pulmonary disease.
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acute necrotizing foot infection, for a 100% 1-year and a
91% 2-year life-table limb salvage rate.
Primary patency rate of the EIA/CFA, as determined
with Kaplan-Meier life-table analysis, was 84%  7% at 12
months (Fig). Five patients had recurrent symptoms and a
reduction in ABI necessitating percutaneous reintervention
at a mean of 7  3 months after the initial procedure
(range, 1 to 17 months). The resultant primary-assisted
patency rate was 97%  3% at 12 months (Fig). Four
patients underwent successful endovascular reintervention,
but in one patient with a hypercoagulable disorder, the
treated EIA/CFA lesion thrombosed, despite reinterven-
tion, necessitating femoral-femoral bypass. No difference
was seen in primary or primary-assisted patency rates be-
tween patients who had or did not have simultaneous distal
revascularization. In patients without bypass, the primary
and primary-assisted patency rates were 83%  11% and
100%, respectively. In patients with distal bypass at the time
of surgery, the rates were 85%  10% and 93%  7%,
respectively (P  .92, with Mantel-Cox log-rank test).
Similarly, patency rates were no different in patients who
did or did not have additional CIA intervention at the
original procedure (P  .24). With logistic regression and
Cox proportional hazard model analyses, no patient-related
factors or lesion characteristics were found to be predictive
of EIA/CFA patency. In particular, no difference was
found in patency on the basis of EIA lesion classification.
DISCUSSION
We used a combined endovascular and open surgical
approach in patients with extensive symptomatic CFA oc-
clusive disease with plaque extension proximal to the ingui-
nal ligament into the EIA. The results of this study showed
that this was an acceptable approach, with a high technical
and hemodynamic success rate, high clinical improvement
rate, high primary and higher primary-assisted patency
rates, and a relatively low complication rate. Although this
was not a prospective comparison with open extended
endarterectomy and patch angioplasty or iliofemoral by-
pass, these results were comparable with the reported ex-
perience with these more invasive procedures. Only five
patients (15%) needed reintervention within the first 18
months, and only one patient had an endovascular failure.
The use of a combined approach to lower extremity
revascularization is not new. Brewster et al27 reported
long-term results after combined iliac angioplasty and distal
reconstruction. They achieved a 76% 5-year patency rate
that improved to an 88% assisted patency rate with reinter-
vention. They believed the value of the combined approach
was to limit the extent of the surgical operation without
compromising the comprehensiveness of the revasculariza-
tion. Reports of the initial experiences of vascular surgeons
with newly acquired endovascular skills describe common
iliac angioplasty to treat inflow stenoses proximal to simul-
taneous femoral-femoral or femoral-distal bypass.21,28-31
Marin et al32 have described an advanced approach with
placement of an iliofemoral stent graft before distal revas-
cularization with excellent safety and performance results.
These various groups have shown that improving the inflow
to a femoral-femoral or femoral-distal reconstruction im-
proves ultimate patency and limb salvage of the overall
reconstruction. In addition, the necessity of an inflow in-
tervention does not seem to put the distal revascularization
at increased risk for failure.33
The best treatment for complex iliofemoral disease is
controversial, with both open and endovascular approaches
having advantages and disadvantages depending on the
details of each case.2 Treatment is best individualized, with
its effectiveness dependent on the appropriate preoperative
assessment and procedure selection. A combined open and
endovascular approach may offer the best features of either
approach alone. Less invasive approaches to treatment of
EIA extension of occlusive disease combined with CFA
endarterectomy have included remote endarterectomy of
the EIA from a single femoral exposure.34,35 Favorable
long-term patency rates of 80% to 83% have been reported
with low morbidity and mortality rates. Technical failure
occurred in 8% of patients as a result of inability to endar-
terectomize the EIA primarily because of significant vessel
calcification. Stents were used selectively on the basis of the
result of the endarterectomy. Our results compare favor-
ably with those of these authors.34,35 Advantages of the
approach described in our study with primary stenting
without debulking may be improved technical success, less
risk of arterial perforation associated with remote endarter-
ectomy, and no apparent limitation because of calcification.
Other approaches have used stent grafts for the treatment
of iliofemoral occlusive disease.12,36 Early patency rates of
80% to 85% have been reported, and all cases necessitated
distal revascularization. Endoluminal grafting may have the
advantage over simple stenting in reduction of intimal
Kaplan-Meier life-table analysis for primary and primary-assisted
EIA/CFA patency rates. Primary patency rate depicted with solid
line, and primary-assisted patency rate with dashed line. Standard
error was less than 10% for both curves over time period shown.
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hyperplasia,37 but this approach is still subject to failure as
the result of repetitive trauma from movement at the hip
joint/inguinal ligament if the stent extends into the CFA.
Previous work in a porcine model has shown that stent
placement across the joint induces a more virulent intimal
hyperplastic response.19
Some important technical aspects of the combined
open and endovascular approach can be gleaned from our
study. The most important technical point is the placement
of the guidewire for the interventional component initially
before endarterectomy. Early in our experience, we at-
tempted to pass the guidewire retrograde into the EIA after
CFA endarterectomy, but this was frequently difficult and
unsuccessful and risks EIA dissection. After adopting the
approach of retrograde placement of the guidewire before
endarterectomy, we have only needed to use a remote
access site in cases of EIA occlusion. In cases of CFA
occlusion mandating endarterectomy before guidewire ac-
cess, a planned contralateral approach from the opposite
femoral artery is advisable and gives equivalent results. This
approach may be limited in patients with bilateral aortoiliac
or iliofemoral disease, and a brachial approach might be
necessary in this situation. A second technical advantage to
the current approach is the superior interface between the
EIA stent and the endarterectomized CFA and patch an-
gioplasty. Alternatively, staging the procedures with initial
EIA stenting followed by CFA endarterectomy and patch
angioplasty would present difficulties with clamping prox-
imal to the planned endarterectomy and with establishing
adequate endarterectomy proximally without interference
from or damaging of the stent.
The use of self-expanding nitinol stents has several
theoretic advantages. These stents are more flexible then
balloon mounted stents and do not foreshorten allowing
precise placement at the distal endpoint. We have preferred
using nitinol stents with radioopaque markers at the ends of
the stent. Nitinol stents in general are not as radioopaque as
other types of stents, and the radioopaque markers facilitate
placement of the stent when using a c-arm fluoroscopy
unit.
Combined CFA endarterectomy and patch angioplasty
with EIA stenting provides a fairly simple yet effective and
durable approach to symptomatic patients with complex
iliofemoral occlusive disease. This procedure effectively
limits the extent of surgical exposure necessary to provide
complete revascularization, resulting in minimal morbidity
and mortality. Our short-term results compare favorably
with ileofemoral bypass and femoral-femoral bypass. One
explanation for the better than expected results of CFA
patch angioplasty with EIA stent placement when com-
pared with treatment of isolated EIA lesions with percuta-
neous transluminal angioplasty/stent is the improved run-
off that is likely after CFA patch angioplasty with associated
profundaplasty. At present, we reserve aortobifemoral by-
pass for young healthy patients with diffuse common and
external iliac occlusive disease. As vascular surgeons attain
greater skill and experience with endovascular techniques,
the treatment of more complex vascular disease with a
combined open and endovascular approach will become
more common.
REFERENCES
1. Brewster DC. Current controversies in the management of aortoiliac
occlusive disease. J Vasc Surg 1997;25:365-79.
2. Lorenzi G, Domanin M, Costantini A, Rolli A, Agrifoglio G. Role of
bypass, endarterectomy, extra-anatomic bypass and endovascular sur-
gery in unilateral iliac occlusive disease: a review of 1257 cases. Cardio-
vasc Surg 1994;2:370-3.
3. Vitale GF, Inahara T. Extraperitoneal endarterectomy for iliofemoral
occlusive disease. J Vasc Surg 1990;12:409-15.
4. Perler BA, Burdick JF, Williams GM. Femoro-femoral or ilio-femoral
bypass for unilateral inflow reconstruction? Am J Surg 1991;161:426-
30.
5. Kalman PG, Hosang M, Johnston KW, Walker PM. Unilateral iliac
disease: the role of iliofemoral bypass. J Vasc Surg 1987;6:139-43.
6. Harrington ME, Harrington EB, Haimov M, Schanzer H, Jacobson JH
II. Iliofemoral versus femorofemoral bypass: the case for an individual-
ized approach. J Vasc Surg 1992;16:841-54.
7. Defraigne JO, Vazquez C, Limet R. Crossover iliofemoral bypass graft-
ing for treatment of unilateral iliac atherosclerotic disease. J Vasc Surg
1999;30:693-700.
8. Darling RC III, Leather RP, Chang BB, Lloyd WE, Shah DM. Is the
iliac artery a suitable inflow conduit for iliofemoral occlusive disease: an
analysis of 514 aortoiliac reconstructions. J Vasc Surg 1993;17:15-22.
9. Powell RJ, Fillinger M, Walsh DB, Zwolak R, Cronenwett JL. Predict-
ing outcome of angioplasty and selective stenting of multisegment iliac
artery occlusive disease. J Vasc Surg 2000;32:564-9.
10. Powell RJ, Bettmann M, Fillinger M, Jeffrey R, Langdon D, Walsh DB.
The durability of endovascular treatment of multisegment iliac occlu-
sive disease. J Vasc Surg 2000;31:1178-84.
11. Onal B, Ilgit ET, Yucel C, Ozbek E, Vural M, Akpek S. Primary stenting
for complex atherosclerotic plaques in aortic and iliac stenoses. Cardio-
vasc Intervent Radiol 1998;21:386-92.
12. Nevelsteen A, Lacroix H, Stockx L, Wilms G. Stent grafts for iliofemoral
occlusive disease. Cardiovasc Surg 1997;5:393-7.
13. Sullivan TM, Childs MB, Bacharach JM, Gray BH, Piedmonte MR.
Percutaneous transluminal angioplasty and primary stenting of the iliac
arteries in 288 patients. J Vasc Surg 1997;25:829-39.
14. Laborde JC, Palmaz JC, Rivera FJ, Encarnacion CE, Picot MC, Dough-
erty SP. Influence of anatomic distribution of atherosclerosis on the
outcome of revascularization with iliac stent placement. J Vasc Interv
Radiol 1995;6:513-21.
15. Henry M, Amor M, Ethevenot G, Henry I, Mentre B, Tzvetanov K.
Percutaneous endoluminal treatment of iliac occlusions: long-term
follow-up in 105 patients. J Endovasc Surg 1998;5:228-35.
16. Ballard JL, Bergan JJ, Singh P, Yonemoto H, Killeen JD. Aortoiliac
stent deployment versus surgical reconstruction: analysis of outcome
and cost. J Vasc Surg 1998;28:94-103.
17. Murphy TP, Webb MS, Lambiase RE, Haas RA, Dorfman GS, Carney
WI. Percutaneous revascularization of complex iliac artery stenoses and
occlusions with use of Wallstents: three-year experience. J Vasc Interv
Radiol 1996;7:21-7.
18. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous
transluminal angioplasty and stent placement for aortoiliac occlusive
disease. Radiology 1997;204:87-96.
19. Andrews RT, Venbrux AC, Magee CA, Bova DA. Placement of a
flexible endovascular stent across the femoral joint: an in vivo study in
the swine model. J Vasc Interv Radiol 1999;10:1219-28.
20. Ballard JL, Sparks SR, Taylor FC, et al. Complications of iliac artery
stent deployment. J Vasc Surg 1996;24:545-55.
21. Hamilton IN Jr, Mathews JA, Sailors DM, Woody JD, Burns RP.
Combination endovascular and open treatment of peripheral arterial
occlusive disease performed by surgeons. Am Surg 1998;64:581-92.
22. Gross GM, Johnson RC, Roberts RM. Results of peripheral endovas-
cular procedures in the operating room. J Vasc Surg 1996;24:353-62.
23. Ahn SS, Rutherford RB, Becker GJ, et al. Reporting standards for lower
extremity arterial endovascular procedures. Society for Vascular Sur-
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 6 Nelson et al 1111
gery/International Society for Cardiovascular Surgery. J Vasc Surg
1993;17:1103-7.
24. Rutherford RB. Reporting standards for endovascular surgery: should
existing standards be modified for newer procedures? Semin Vasc Surg
1997;10:197-205.
25. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
26. Pentecost MJ, Criqui MH, Dorros G, Goldstone J, Johnston KW,
Martin EC, et al. Guidelines for peripheral percutaneous transluminal
angioplasty of the abdominal aorta and lower extremity vessels. A
statement for health professionals from a special writing group of the
Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Tho-
racic and Vascular Surgery, Clinical Cardiology, and Epidemiology and
Prevention, the American Heart Association. Circulation 1994;89:511-
31.
27. Brewster DC, Cambria RP, Darling RC, Athanasoulis CA, Waltman
AC, Geller SC, et al. Long-term results of combined iliac balloon
angioplasty and distal surgical revascularization. Ann Surg 1989;210:
324-31.
28. Aburahma AF, Robinson PA, Cook CC, Hopkins ES. Selecting
patients for combined femorofemoral bypass grafting and iliac bal-
loon angioplasty and stenting for bilateral iliac disease. J Vasc Surg
2001;33:S93-9.
29. Demasi RJ, Snyder SO, Wheeler JR, Gregory RT, Gayle RG, Parent FN,
et al. Intraoperative iliac artery stents: combination with infra-inguinal
revascularization procedures. Am Surg 1994;60:854-9.
30. Faries PL, Brophy D, LoGerfo FW, Akbari CM, Campbell DR, Spence
LD, et al. Combined iliac angioplasty and infrainguinal revasculariza-
tion surgery are effective in diabetic patients with multilevel arterial
disease. Ann Vasc Surg 2001;15:67-72.
31. Perler BA, Williams GM. Does donor iliac artery percutaneous translu-
minal angioplasty or stent placement influence the results of femoro-
femoral bypass? Analysis of 70 consecutive cases with long-term follow-
up. J Vasc Surg 1996;24:363-70.
32. Marin ML, Veith FJ, Sanchez LA, Cynamon J, Suggs WD, Schwartz
ML, et al. Endovascular aortoiliac grafts in combination with standard
infrainguinal arterial bypasses in the management of limb-threatening
ischemia: preliminary report. J Vasc Surg 1995;22:316-25.
33. Eagleton MJ, Illig KA, Green RM, Ouriel K, Riggs PN, DeWeese JA.
Impact of inflow reconstruction on infrainguinal bypass. J Vasc Surg
1997;26:928-38.
34. van den Dungen JJ, Boontje AH, Kropveld A. Unilateral iliofemoral
occlusive disease: long-term results of the semi-closed endarterectomy
with the ring-stripper. J Vasc Surg 1991;14:673-7.
35. Queral LA, Criado FJ, Patten P. Retrograde iliofemoral endarterectomy
facilitated by balloon angioplasty. J Vasc Surg 1995;22:742-50.
36. Cynamon J, Marin ML, Veith FJ, Bakal CW, Wahl SI, DiBartholomeo
TJ, et al. Stent-graft repair of aorto-iliac occlusive disease coexisting
with common femoral artery disease. J Vasc Interv Radiol 1997;8:19-
26.
37. Diethrich EB. Endoluminal grafting in the treatment of iliac and
superficial femoral artery disease. Tex Heart Inst J 1997;24:185-92.
Submitted Oct 15, 2001; accepted Jan 25, 2002.
DISCUSSION
Dr William Abbott (Boston, Mass). Peter, I would echo
what Jim Menzoian said. This is a very fascinating approach, and I
really have two technical questions, which if I sat back maybe I
would be able to figure out. But would you tell me, number one,
why you did the procedures in the order you did—in other words,
the endarterectomy and patch first and then the balloon angio-
plasty stent second?
Dr Peter Nelson. I think the concept there is that you want
to create a smooth transition between the stented portion of the
lesion and the endarterectomized femoral artery. If you cut your
proximal endarterectomy end point flush and then stent across
that, I think it creates a smoother transition, whereas if you did it
opposite and placed your stent you would be grappling with two
issues: one, how to clamp and get proximal control with the stent
now in place, and, number two, how to not damage or bend the
stent trying to get the last little bit of endarterectomy done.
Dr Abbott. That makes sense. The second question is, how
do you get the wire back out through the patch?
Dr Nelson. What we do is, with the patch either free before
we start to anastomose or just before we finish the anastomosis, we
use the puncture needle to poke through the patch and then
advance the wire retrograde out through the needle.
Dr Jens Jorgensen (Portland, Me). It is my understanding
that the external iliac occlusive disease is oftentimes a marker for a
poor predictor of outcome following angioplasty. Why does it
seem to work in this situation?
Dr Nelson. We asked ourselves that same question. As you
know, Dr Powell and the group at Dartmouth have spent a lot of
time looking at interventional treatment of aortoiliac occlusive
disease and have found that external iliac disease is a poor predictor
and that you can actually stratify patients based on the extent of
their external iliac disease. I think in some way these patients
represent a different category of patients. They generally do not
have diffuse aortoiliac disease and, for some reason, have focal
iliofemoral disease, and often unilaterally. In this particular case,
we are as interested as you are as to why the external iliac interven-
tions do so well, whereas if they have diffuse common and external
iliac disease, the external iliac disease is the predictor of poor
outcome. I think they may be a slightly different patient group.
Dr Andrew C. Stanley (Burlington, Vt). Peter, two quick
questions. With a rather extensive groin procedure with a pros-
thetic patch in there, did you have any infectious complications?
Do you have any idea what your complication rate is in comparison
with a traditional aortofemoral or iliofemoral?
Secondly, with kind of unilateral disease, do you have any idea
as to how many of your patients had prior percutaneous translu-
minal angioplastys or cardiac catheters before you saw them for
their symptomatic disease?
Dr Nelson. To answer your first question, we had a 15%
incidence rate of complications, and two of those were minor
wound infections. So, yes, wound infections are an issue. They
were both limited, not involving patch infection. We did not
compare that directly with a subset of patients with aortofemoral or
femorofemoral bypass, but it is a fairly low incidence rate of wound
problems.
The second answer is that two patients in this study group had
previous common iliac artery intervention. I am not aware and I do
not have data as to how many had cardiac catheterizations prior to
this procedure, but two patients did have previous iliac interven-
tion.
Dr Daniel Gorin (Hyannis, Mass). Two quick questions. I
think this is a really elegant approach to this. It is very appealing.
One question is, what preoperative imaging did you routinely
use before you took these patients to the operating room? Did they
have arteriography, or did you use noninvasive methods?
The second question is technical. At what point did you end
the proximal end of your patch and your endarterectomy? Was it
right at the inguinal ligament or some distance above it? How low
or high did you need to get the end of that stent to make it safe in
terms of the groin crease and so on?
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Dr Nelson. Thank you. The first question with respect to
preoperative workup. All these patients were worked up with both
physical examination, ABIs, and preoperative duplex scan. None of
the patients had preoperative arteriogram, but all obviously had
intraoperative arteriography. That reflects our practice at Dartmouth
with duplex scanning aggressively for preoperative evaluation.
With respect to the proximal extent of endarterectomy and
patch, it was the purpose of this not to divide the inguinal ligament,
and so, by definition, in no patient did that occur. The extent of the
arteriotomy and the endarterectomy in the subsequent patch clo-
sure was proximal to the inguinal ligament as much as we could
retract with a femoral retractor to get up higher, so we did not
measure the distance. But you are looking at probably 1 cm of
distance above, just so that the external iliac stent could not
traverse the inguinal ligament.
Dr Randolph Maloney (Beverly, Mass). Well, I thank you
very much for the paper because it is a very useful technique,
although my thinking is to do it the other way around. I believe
you should establish inflow first. If you cannot get across, then you
can always do a retroperitoneal approach or whatever. As a techni-
cal aside, I would mention that once you have this stent placed, it
is not too hard to extend your endarterectomy a little bit above the
inguinal ligament and then under fluoroscopic control know ex-
actly where your stent is. Because if it gets misplaced or requires
any dilatation or anything, it can be disastrous if there is a bleed in
that area. Having it open, you can control it with in-line balloons,
which we do. We will do the stenting first and then do the
endarterectomy, controlling the inflow with a Fogarty embolec-
tomy balloon or, if that keeps popping too much because there is a
problem with that, you can place a small Foley catheter in which
the latex is a little bit stronger and you can still perform your
procedure.
I am wondering if you had problems during this time—I saw
you came over from the contralateral side a couple of times because
you can get through. Did you consider possibly just abandoning
and going retroperitoneal to get above the area, which is a pretty
simple operation and pretty safe in even a high-risk patient?
Dr Nelson. Thanks. You bring up some good technical
points. We did not in any of these patients need to go with a
retroperitoneal counterincision to expose that, although obviously
that is your ultimate option to achieve proximal control and, even
if need be, do an iliofemoral bypass as your backup open proce-
dure. Between the options of direct wire access through the
arteriotomy or, as I depicted, a puncture of the common femoral
initially, a contralateral femoral artery puncture, and finally the
option of a brachial approach, we felt pretty confident that we
could in some way attain wire access through the lesion, and so we
did not primarily consider to use an adjunctive incision. You do
bring up a good point though, and the reason for having other
alternatives for wire access is that if you have common femoral
occlusion, obviously the puncture option is no longer available.
Then you try to open the femoral artery and find the lumen and
pass the wire, but that can be very tricky and obviously very risky for
dissection of the external iliac artery if you do not get the wire
directly within the lumen. That is where a fairly low threshold
approach to the contralateral percutaneous approach should be
utilized.
Dr Michael Southworth (Somersworth, NH). It is a very
appealing approach, but my philosophy is always to think about
what you have to do next, and the procedure seems to turn the
groin into a fairly hostile environment as far as returning and
placing clamps in the future. What is your thought on that?
Dr Nelson. You bring up a good point; however, I think with
the configuration that we had on the schematic slide, if these
patients, number one, recur, our first approach would be a percu-
taneous evaluation and probably treatment, as in five patients in
this study group. If they ever needed a femorofemoral bypass or an
aortofemoral bypass, then in that situation we would probably
control our inflow with a balloon, as was pointed out earlier.
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